Source: ERJ Open Res, 7 (3) 00273-2021; 10.1183/23120541.00273-2021
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Claire A. Butler, Alan J. McMichael, Kirsty Honeyford, Louise Wright, Jayne Logan, Joshua Holmes, John Busby, Catherine E. Hanratty, Freda Yang, Steven J. Smith, Kirsty Murray, Rekha Chaudhuri, Liam G. Heaney. Utility of fractional exhaled nitric oxide suppression as a prediction tool for progression to biologic therapy. ERJ Open Res, 7 (3) 00273-2021; 10.1183/23120541.00273-2021

Member's Comments

No comment yet.

Related content which might interest you: Investigation on the effectiveness of the Mostgraph and fractional exhaled nitric oxide measurement in chronic cough Source: Annual Congress 2012 - Exhaled biomarkers in airway diseases Year: 2012 Clinical utility of fractional exhaled nitric oxide in severe asthma management Source: Eur Respir J, 55 (3) 1901633; 10.1183/13993003.01633-2019 Year: 2020 Clinical usefulness of fractional exhaled nitric oxide (FeNO) as a marker of long-term asthma control Source: Annual Congress 2009 - Airway inflammation and asthma control Year: 2009 Is exhaled nitric oxide measurement useful in clinical practice? Source: ISSN=ISSN 1810-6838, ISBN=, page=185 Year: 2006 Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model Source: Eur Respir J 2006; 28: 1236-1244 Year: 2006 Increased levels of fractional exhaled nitric oxide after chemotherapy for lung cancer. Ongoing study Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Usefulness of fractional exhaled nitric oxide (FeNO) as a marker of asthma control Source: Annual Congress 2008 - Phenotyping of asthma and COPD Year: 2008 Predicting response to corticosteroid in COPD using exhaled nitric oxide Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Utility of fractional exhaled nitric oxide (FeNO) in assessing asthma control following inhaled corticosteroid treatment Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016 Comparison of exhaled nitric oxide values measured by two offline methods or NO breath Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Accuracy of exhaled nitric oxide to predict a loss of asthma control in well-controlled patients Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases Year: 2010 Exhaled nitric oxide as a biomarker in different COPD phenotypes Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018 Value of exhaled nitric oxide in the evaluation of disease activity in sarcoidosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 174s Year: 2002 The source of exhaled nitric oxide does not correlate with clinical markers in interstitial lung disease Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007 Fractional exhaled nitric oxide (FeNO) for an early diagnosis of asthma Source: Eur Respir J 2006; 28: Suppl. 50, 677s Year: 2006 Extended measurement of exhaled nitric oxide in patients after lung transplantation Source: Eur Respir J 2005; 26: Suppl. 49, 705s Year: 2005 Fractional exhaled nitric oxide (FeNO) suppression with directly observed inhaled corticosteroid therapy: does it make a difference to patient outcomes? Source: International Congress 2018 – Clinical and functional monitoring in airway disease Year: 2018 Technical problems with measurements of biomarkers - exhaled nitric oxide Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases Year: 2017 The assessment of exhaled nitric oxide fraction in monitoring asthma control: How to raise the clinical relevance? Source: Annual Congress 2010 - Cough, airway hyperresponsiveness and asthma control Year: 2010